Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 361 to 375 of 1309 results for long term conditions

  1. Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention (HTG685)

    Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.

  2. Intramedullary distraction for upper limb lengthening (HTG621)

    Evidence-based recommendations on intramedullary distraction for upper limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter arm.

  3. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

  4. Integrated health and social care for people experiencing homelessness (NG214)

    This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.

  5. Diabetes: admission rates (complications) (IND40)

    This indicator covers admission rates for people with diabetes due to complications associated with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG58

  6. Bronchial thermoplasty for severe asthma (HTG494)

    Evidence-based recommendations on bronchial thermoplasty for severe asthma in adults. This involves applying heat to the inside walls of the airways.

  7. Kidney conditions: CKD – eGFR and ACR (IND234)

    This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a-G5 (on the register, within the preceding 12 months) who had eGFR and ACR (urine albumin to creatinine ratio) measurements recorded within 90 days before or after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM216

  8. Head injury: assessment and early management (NG232)

    This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

  9. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.

  10. Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

    Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.

  11. Diabetes: admission rates (angina) (IND41)

    This indicator covers admission rates due to angina in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG59

  12. Diabetes: annual dietary review (IND89)

    This indicator covers the percentage of patients with diabetes who have a record of a dietary review by a suitably competent professional in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM28

  13. Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

    Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

  14. Temperature control to improve neurological outcomes after cardiac arrest (HTG710)

    Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).

  15. Open prenatal repair for open neural tube defects in the fetus (HTG537)

    Evidence-based recommendations on open prenatal repair of open neural tube defects in the fetus. This involves open surgery through the woman’s abdomen to close the gap in the baby’s spine.